E. David G. McIntosh
Research Subjects
Research Interests
E. David G. McIntosh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
A. Lloyd
1 shared publicationAdam Lloyd
1 shared publicationB. Fritzell
International Scientific & Clinical Affairs, Wyeth Vaccines Research, Paris, France
1 shared publicationFj Malinoski
1 shared publicationJ. Willingham
1 shared publicationJulie Willingham
1 shared publication
Latest Publications
- 20 October 2008
- Published by Springer Nature
- Vol. 634, 153-159
Paediatric Drug Development and Clinical Trials
- 20 October 2008
- Published by Springer Nature
- Vol. 634, 153-159
Paediatric Drug Development and Clinical Trials
- 7 September 2006
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 135 (4) , 644-656
Burden of paediatric invasive pneumococcal disease in Europe, 2005
SUMMARYWithin the European Union (EU), documenting the burden of invasive pneumococcal disease (IPD) in infants and children is important for coordinating effective pneumococcal immunization policies. Our objective was to document the burden of IPD in countries of the EU plus Switzerland and Norway. European affiliates of Wyeth Vaccines made available recent epidemiological data on IPD from local disease surveillance programmes, including unpublished sources. Recent literature and websites were also searched to provide as wide a representation as possible. This included OVID and abstracts from a number of international meetings, dating from the year 2000. The reported rates of paediatric IPD per 100 000 (age) ranged from a low of 1·7 (
- 7 September 2006
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 135 (4) , 644-656
Burden of paediatric invasive pneumococcal disease in Europe, 2005
SUMMARYWithin the European Union (EU), documenting the burden of invasive pneumococcal disease (IPD) in infants and children is important for coordinating effective pneumococcal immunization policies. Our objective was to document the burden of IPD in countries of the EU plus Switzerland and Norway. European affiliates of Wyeth Vaccines made available recent epidemiological data on IPD from local disease surveillance programmes, including unpublished sources. Recent literature and websites were also searched to provide as wide a representation as possible. This included OVID and abstracts from a number of international meetings, dating from the year 2000. The reported rates of paediatric IPD per 100 000 (age) ranged from a low of 1·7 (
- 1 August 2004
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 3 (4) , 433-442
Cost-effectiveness studies of pneumococcal conjugate vaccines
The 7-valent pneumococcal conjugate vaccine is licensed in many countries for the prevention of pediatric pneumococcal disease. The vaccine is known to be highly immunogenic in infants and young children, and has been shown to be efficacious not only in decreasing disease in pediatric age groups but also in adults through herd immunity. Cost-effectiveness analyses of this vaccine have been performed in a number of countries. The present review compiles, summarizes and critiques these analyses. The range of values for cost-effectiveness, as measured in cost per life-years gained, in the studies reviewed, ranges from 14,000 US dollars to 147,000 US dollars with one outlier at 504,000 US dollars. For cost per quality-adjusted life years the range is 26,000 US dollars to 66,000 US dollars. Recommendations for the use of the vaccine will take account not only of these ratios but also of the absolute burden of disease. Performing cost-effectiveness analyses for healthcare interventions in infants and children is one means of redressing inequalities.
- 1 August 2004
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 3 (4) , 433-442
Cost-effectiveness studies of pneumococcal conjugate vaccines
The 7-valent pneumococcal conjugate vaccine is licensed in many countries for the prevention of pediatric pneumococcal disease. The vaccine is known to be highly immunogenic in infants and young children, and has been shown to be efficacious not only in decreasing disease in pediatric age groups but also in adults through herd immunity. Cost-effectiveness analyses of this vaccine have been performed in a number of countries. The present review compiles, summarizes and critiques these analyses. The range of values for cost-effectiveness, as measured in cost per life-years gained, in the studies reviewed, ranges from 14,000 US dollars to 147,000 US dollars with one outlier at 504,000 US dollars. For cost per quality-adjusted life years the range is 26,000 US dollars to 66,000 US dollars. Recommendations for the use of the vaccine will take account not only of these ratios but also of the absolute burden of disease. Performing cost-effectiveness analyses for healthcare interventions in infants and children is one means of redressing inequalities.
- 1 August 2004
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 3 (4) , 353-357
Vaccines for neonatal viral infections: Towards a live respiratory syncytial virus vaccine: a study in risk
There is risk attached to the development of respiratory syncytial virus vaccines, live attenuated or otherwise, but without the acceptance of this risk by manufacturers, health providers and the public, the conclusion of successful Phase III trials may lie in the distant future.
- 1 August 2004
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 3 (4) , 353-357
Vaccines for neonatal viral infections: Towards a live respiratory syncytial virus vaccine: a study in risk
There is risk attached to the development of respiratory syncytial virus vaccines, live attenuated or otherwise, but without the acceptance of this risk by manufacturers, health providers and the public, the conclusion of successful Phase III trials may lie in the distant future.
- Open Access
- 1 October 2003
- Published by BMJ in Archives of Disease in Childhood
- Vol. 88 (10) , 859-861
How many episodes of hospital care might be prevented by widespread uptake of pneumococcal conjugate vaccine?
Background: It is likely that disease specific infectious morbidity is under-reported. Microbiologically identifiable diseases may be “hidden” in ICD-10 code as “unspecified” disease. Aims: To estimate the proportion of “unspecified” morbidity of infectious cause in infants and young children reported by Hospital Episode Statistics (HES) in England in 1999 that could reasonably be attributed to Streptococcus pneumoniae, and to calculate what number and proportion of diseases could potentially be prevented by a programme of pneumococcal conjugate vaccination. Methods: Proportions of HES “unspecified” septicaemia, meningitis, and pneumonia attributable to pneumococcal infection were estimated by applying theoretical rates obtained from studies using highly sensitive diagnostic tests. The numbers obtained were added to those coded as pneumococcal in origin. The vaccine preventable proportion was then calculated using serogroup coverage, disease specific efficacy, and vaccine uptake. Results: For infants and children 3 months to 5 years of age in 1999, HES reported 134, 245, and 216 episodes of pneumococcal septicaemia, meningitis, and pneumonia respectively. In addition, 68, 36, and 2548 episodes of “unspecified” disease respectively are probably pneumococcal in origin. For hospitalisations in England in this age group, 157/202 (78%) cases of pneumococcal septicaemia, 218/281 (76%) cases of pneumococcal meningitis, and 452/2764 (16%) cases of pneumococcal pneumonia may be preventable annually by means of pneumococcal conjugate vaccination. Conclusions: Paediatric hospital morbidity in England due to pneumococcal septicaemia, meningitis, and pneumonia is under-reported by 34%, 13% and 92% respectively. A larger proportion of morbidity is preventable than implied by ICD-10 code alone.
- 1 October 2003
- Published by BMJ in Archives of Disease in Childhood
- Vol. 88 (10) , 859-861
Open AccessHow many episodes of hospital care might be prevented by widespread uptake of pneumococcal conjugate vaccine?
Background: It is likely that disease specific infectious morbidity is under-reported. Microbiologically identifiable diseases may be “hidden” in ICD-10 code as “unspecified” disease. Aims: To estimate the proportion of “unspecified” morbidity of infectious cause in infants and young children reported by Hospital Episode Statistics (HES) in England in 1999 that could reasonably be attributed to Streptococcus pneumoniae, and to calculate what number and proportion of diseases could potentially be prevented by a programme of pneumococcal conjugate vaccination. Methods: Proportions of HES “unspecified” septicaemia, meningitis, and pneumonia attributable to pneumococcal infection were estimated by applying theoretical rates obtained from studies using highly sensitive diagnostic tests. The numbers obtained were added to those coded as pneumococcal in origin. The vaccine preventable proportion was then calculated using serogroup coverage, disease specific efficacy, and vaccine uptake. Results: For infants and children 3 months to 5 years of age in 1999, HES reported 134, 245, and 216 episodes of pneumococcal septicaemia, meningitis, and pneumonia respectively. In addition, 68, 36, and 2548 episodes of “unspecified” disease respectively are probably pneumococcal in origin. For hospitalisations in England in this age group, 157/202 (78%) cases of pneumococcal septicaemia, 218/281 (76%) cases of pneumococcal meningitis, and 452/2764 (16%) cases of pneumococcal pneumonia may be preventable annually by means of pneumococcal conjugate vaccination. Conclusions: Paediatric hospital morbidity in England due to pneumococcal septicaemia, meningitis, and pneumonia is under-reported by 34%, 13% and 92% respectively. A larger proportion of morbidity is preventable than implied by ICD-10 code alone.
- Open Access
- 1 June 2002
- Published by BMJ in Archives of Disease in Childhood
- Vol. 86 (6) , 403-406
Invasive pneumococcal disease in England and Wales: what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine?
Background: The annual reported incidence rates for laboratory confirmed invasive pneumococcal disease (IPD) underestimate the true burden of invasive disease attributable to pneumococcal infection. Aims: To estimate the proportion of “unspecified” mortality of infectious cause in infants and young children aged 1 month to 4 years reported by the Office for National Statistics (ONS) in England and Wales that could reasonably be attributed to IPD, thereby revising the total number of deaths per year potentially attributable to IPD, and producing a more accurate figure for the number of deaths that may be prevented by a programme of pneumococcal conjugate vaccination. Methods: Polymerase chain reaction, latex agglutination, and other alternate methodologies to microbiological culture have been applied in various studies to the detection of Streptococcus pneumoniae. Some of these tests have been shown to be more sensitive indicators of pneumococcal infection. In our analysis the implications of these tests were applied theoretically to the “unspecified” clinical deaths caused by septicaemia, meningitis, and pneumonia reported by the ONS, with a 20% correction/reduction factor for nasopharyngeal carriage which these sensitive tests may coincidentally detect. Results: The ONS reported an average of 13 deaths per year (1989–99) in infants and children aged 1 month to 4 years caused by pneumococcal septicaemia, meningitis, or pneumonia. By applying the rates for the more sensitive tests to the most recent ONS “unspecified” mortality data available (1999), the actual annual number of deaths caused by IPD in the age group 1 month to 4 years is shown to be at least as high as 43. Conclusions: The mortality as a result of IPD in infants and young children may be at least three times the reported rate. The 7 valent pneumococcal conjugate vaccine may have the potential to prevent up to 26 (61%) of the IPD deaths per year in infants and young children in England and Wales alone.
- 1 June 2002
- Published by BMJ in Archives of Disease in Childhood
- Vol. 86 (6) , 403-406
Open AccessInvasive pneumococcal disease in England and Wales: what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine?
Background: The annual reported incidence rates for laboratory confirmed invasive pneumococcal disease (IPD) underestimate the true burden of invasive disease attributable to pneumococcal infection. Aims: To estimate the proportion of “unspecified” mortality of infectious cause in infants and young children aged 1 month to 4 years reported by the Office for National Statistics (ONS) in England and Wales that could reasonably be attributed to IPD, thereby revising the total number of deaths per year potentially attributable to IPD, and producing a more accurate figure for the number of deaths that may be prevented by a programme of pneumococcal conjugate vaccination. Methods: Polymerase chain reaction, latex agglutination, and other alternate methodologies to microbiological culture have been applied in various studies to the detection of Streptococcus pneumoniae. Some of these tests have been shown to be more sensitive indicators of pneumococcal infection. In our analysis the implications of these tests were applied theoretically to the “unspecified” clinical deaths caused by septicaemia, meningitis, and pneumonia reported by the ONS, with a 20% correction/reduction factor for nasopharyngeal carriage which these sensitive tests may coincidentally detect. Results: The ONS reported an average of 13 deaths per year (1989–99) in infants and children aged 1 month to 4 years caused by pneumococcal septicaemia, meningitis, or pneumonia. By applying the rates for the more sensitive tests to the most recent ONS “unspecified” mortality data available (1999), the actual annual number of deaths caused by IPD in the age group 1 month to 4 years is shown to be at least as high as 43. Conclusions: The mortality as a result of IPD in infants and young children may be at least three times the reported rate. The 7 valent pneumococcal conjugate vaccine may have the potential to prevent up to 26 (61%) of the IPD deaths per year in infants and young children in England and Wales alone.